JP5588441B2 - Ｐｓｍａ結合剤及びその使用 - Google Patents

Ｐｓｍａ結合剤及びその使用 Download PDF

Info

Publication number
JP5588441B2
JP5588441B2 JP2011521362A JP2011521362A JP5588441B2 JP 5588441 B2 JP5588441 B2 JP 5588441B2 JP 2011521362 A JP2011521362 A JP 2011521362A JP 2011521362 A JP2011521362 A JP 2011521362A JP 5588441 B2 JP5588441 B2 JP 5588441B2
Authority
JP
Japan
Prior art keywords
compound
radioactive isotope
iodine
fluorine
bromine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011521362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529919A (ja
JP2011529919A5 (enExample
Inventor
マーティン ギルバート ポンパー
ロニー チャールズ ミーズ
イン チェン
Original Assignee
ザ ジョンズ ホプキンズ ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジョンズ ホプキンズ ユニヴァーシティー filed Critical ザ ジョンズ ホプキンズ ユニヴァーシティー
Publication of JP2011529919A publication Critical patent/JP2011529919A/ja
Publication of JP2011529919A5 publication Critical patent/JP2011529919A5/ja
Application granted granted Critical
Publication of JP5588441B2 publication Critical patent/JP5588441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)
JP2011521362A 2008-08-01 2009-07-31 Ｐｓｍａ結合剤及びその使用 Active JP5588441B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8546208P 2008-08-01 2008-08-01
US61/085,462 2008-08-01
US11179108P 2008-11-06 2008-11-06
US61/111,791 2008-11-06
PCT/US2009/052456 WO2010014933A2 (en) 2008-08-01 2009-07-31 Psma-binding agents and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014152130A Division JP5806765B2 (ja) 2008-08-01 2014-07-25 Ｐｓｍａ結合剤及びその使用

Publications (3)

Publication Number Publication Date
JP2011529919A JP2011529919A (ja) 2011-12-15
JP2011529919A5 JP2011529919A5 (enExample) 2012-09-20
JP5588441B2 true JP5588441B2 (ja) 2014-09-10

Family

ID=41610978

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011521362A Active JP5588441B2 (ja) 2008-08-01 2009-07-31 Ｐｓｍａ結合剤及びその使用
JP2014152130A Active JP5806765B2 (ja) 2008-08-01 2014-07-25 Ｐｓｍａ結合剤及びその使用
JP2015174731A Active JP6030724B2 (ja) 2008-08-01 2015-09-04 Ｐｓｍａ結合剤及びその使用
JP2016206120A Active JP6524046B2 (ja) 2008-08-01 2016-10-20 Ｐｓｍａ結合剤及びその使用
JP2018220353A Active JP7277113B2 (ja) 2008-08-01 2018-11-26 Ｐｓｍａ結合剤及びその使用
JP2021012046A Active JP7219497B2 (ja) 2008-08-01 2021-01-28 Ｐｓｍａ結合剤及びその使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014152130A Active JP5806765B2 (ja) 2008-08-01 2014-07-25 Ｐｓｍａ結合剤及びその使用
JP2015174731A Active JP6030724B2 (ja) 2008-08-01 2015-09-04 Ｐｓｍａ結合剤及びその使用
JP2016206120A Active JP6524046B2 (ja) 2008-08-01 2016-10-20 Ｐｓｍａ結合剤及びその使用
JP2018220353A Active JP7277113B2 (ja) 2008-08-01 2018-11-26 Ｐｓｍａ結合剤及びその使用
JP2021012046A Active JP7219497B2 (ja) 2008-08-01 2021-01-28 Ｐｓｍａ結合剤及びその使用

Country Status (24)

Country Link
US (7) US8778305B2 (enExample)
EP (3) EP2318366B1 (enExample)
JP (6) JP5588441B2 (enExample)
KR (1) KR101664855B1 (enExample)
CN (3) CN102171187B (enExample)
AU (1) AU2009276423B2 (enExample)
CA (2) CA2987744C (enExample)
CY (3) CY1119367T1 (enExample)
DK (2) DK2318366T3 (enExample)
ES (2) ES2634894T3 (enExample)
FI (1) FIC20230033I1 (enExample)
FR (1) FR23C1044I2 (enExample)
HK (1) HK1247197A1 (enExample)
HR (2) HRP20220742T1 (enExample)
HU (3) HUE034027T2 (enExample)
LT (3) LT3222615T (enExample)
NL (1) NL301250I2 (enExample)
NO (1) NO2024006I1 (enExample)
PL (2) PL3222615T3 (enExample)
PT (2) PT3222615T (enExample)
RU (1) RU2494096C2 (enExample)
SI (2) SI2318366T1 (enExample)
SM (1) SMT201700371T1 (enExample)
WO (1) WO2010014933A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048204A (ja) * 2008-08-01 2017-03-09 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａ結合剤及びその使用

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583931A (en) 2007-08-17 2012-06-29 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US8855387B2 (en) 2007-12-28 2014-10-07 Exini Diagnostics Ab System for detecting bone cancer metastases
EP2433322A4 (en) 2009-05-19 2015-11-04 East Penn Mfg Co COMPOSITE CURRENT COLLECTOR AND RELATED METHODS
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US9371360B2 (en) 2011-11-30 2016-06-21 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
KR102575825B1 (ko) * 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US11554183B2 (en) * 2013-03-15 2023-01-17 Cancer Targeted Technology Llc 18F-labeled PSMA-targeted PET imaging agents
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
SG11201602249RA (en) 2013-10-18 2016-05-30 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP6292568B2 (ja) * 2013-11-06 2018-03-14 国立大学法人京都大学 ウレア誘導体化合物、これを含有する放射性医薬
EA035171B1 (ru) 2013-11-14 2020-05-08 Эндосайт, Инк. Конъюгаты на основе связывающихся с psma лигандов или ингибиторов psma для позитронно-эмиссионной томографии
US9713649B2 (en) 2014-01-24 2017-07-25 The Cleveland Clinic Foundation PSMA-targeting imaging agents
WO2015153772A2 (en) 2014-04-01 2015-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
ES2912753T3 (es) 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
EP2993171A1 (en) * 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
EP3011976A1 (en) * 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016112382A2 (en) * 2015-01-09 2016-07-14 The Johns Hopkins University Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors
US10869940B2 (en) 2015-06-12 2020-12-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted photoacoustic compounds, formulations, and uses thereof
US20180236109A1 (en) * 2015-08-20 2018-08-23 Universitat Zu Koln Pain Tracking by PET-imaging (Pain-TraP)
HRP20210183T1 (hr) 2015-09-30 2021-04-30 Deutsches Krebsforschungszentrum 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate
US20200231614A1 (en) * 2015-10-22 2020-07-23 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
EP3400229B1 (en) 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
LT3481804T (lt) * 2016-06-10 2025-02-25 The Johns Hopkins University Radioaktyviai pažymėto prostatos specifinio membranos antigeno (psma) inhibitoriaus [18f]dcfpyl pagerinta sintezė
WO2017223357A1 (en) * 2016-06-23 2017-12-28 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
AU2017348111B2 (en) 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
JP6999960B2 (ja) * 2016-11-17 2022-01-19 思路迪（北京）医薬科技有限公司 抗がん作用を有する化合物およびその製造方法ならびにその使用
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
JP7284707B2 (ja) * 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
WO2018236115A1 (ko) 2017-06-19 2018-12-27 (주)퓨쳐켐 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
LT3643707T (lt) * 2017-06-19 2022-05-25 Futurechem Co., Ltd. 18f žymėtas junginys, skirtas prostatos vėžio diagnostikai ir jo panaudojimas
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
EP4008359B1 (en) * 2017-12-11 2024-09-11 Technische Universität München Psma ligands for imaging and endoradiotherapy
US10973486B2 (en) 2018-01-08 2021-04-13 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
ES3026214T3 (en) 2018-01-08 2025-06-10 Progenics Pharm Inc System and method for rapid neural network-based image segmentation
IL276528B2 (en) * 2018-02-06 2024-11-01 Univ Johns Hopkins PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
BR112020020961A2 (pt) 2018-04-17 2021-01-19 Endocyte, Inc. Métodos de tratamento de câncer
CN109160896B (zh) * 2018-05-16 2021-06-25 上海如絮生物科技有限公司 一种亲水性吡啶类化合物中间体及其制备方法
CN109160899B (zh) * 2018-05-16 2021-06-04 上海如絮生物科技有限公司 一种亲水性吡啶类化合物、中间体、其制备方法及应用
CN109160898B (zh) * 2018-05-16 2021-06-04 上海如絮生物科技有限公司 一种亲水性吡啶类化合物中间体及其制备方法
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
CA3115806A1 (en) 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Combination therapy for treating metastatic prostate cancer
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
US11657508B2 (en) 2019-01-07 2023-05-23 Exini Diagnostics Ab Systems and methods for platform agnostic whole body image segmentation
PL239934B1 (pl) * 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
US11948283B2 (en) 2019-04-24 2024-04-02 Progenics Pharmaceuticals, Inc. Systems and methods for interactive adjustment of intensity windowing in nuclear medicine images
TWI872062B (zh) 2019-04-24 2025-02-11 美商普吉尼製藥公司 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法
CN120097929A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
CN119431260A (zh) 2019-06-21 2025-02-14 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
CA3149598A1 (en) * 2019-08-30 2021-03-04 Naga Vara Kishore PILLARSETTY Novel theranostic agents for psma positive cancers
US11564621B2 (en) 2019-09-27 2023-01-31 Progenies Pharmacenticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11544407B1 (en) 2019-09-27 2023-01-03 Progenics Pharmaceuticals, Inc. Systems and methods for secure cloud-based medical image upload and processing
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
KR102269315B1 (ko) 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
US11321844B2 (en) 2020-04-23 2022-05-03 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
US11386988B2 (en) 2020-04-23 2022-07-12 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
CN111548305B (zh) * 2020-05-12 2021-08-31 北京师范大学 一种可用于靶向psma的喹啉类化合物及其制备方法
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
WO2022008374A1 (en) 2020-07-06 2022-01-13 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20240072996A (ko) 2021-07-30 2024-05-24 오사카 유니버시티 방사성 표지된 화합물 및 이의 용도
US20230115732A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
EP4429654A4 (en) 2021-11-09 2025-07-09 Univ Case Western Reserve PSMA-TARGETED CONJUGATE COMPOUNDS AND THEIR USES
CN119325617A (zh) 2022-06-08 2025-01-17 普罗热尼奇制药公司 评估疾病负荷和进展的系统和方法
EP4648799A1 (en) 2023-01-10 2025-11-19 Sun Pharma Advanced Research Company Ltd Ligand-drug conjugates
US20240285248A1 (en) 2023-02-13 2024-08-29 Progenics Pharmaceuticals, Inc. Systems and methods for predicting biochemical progression free survival in prostate cancer patients
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
WO2024211651A1 (en) 2023-04-07 2024-10-10 Progenics Pharmaceuticals, Inc. Systems and methods for facilitating lesion inspection and analysis
WO2025072177A1 (en) 2023-09-25 2025-04-03 Progenics Pharmaceuticals, Inc. Systems and methods for automated cancer staging and risk prediction
WO2025090594A1 (en) * 2023-10-25 2025-05-01 The Johns Hopkins University Deep transfer learning for fully automated tumor quantification and prognosis of cancer on pet/ct
DE102023133281B8 (de) * 2023-11-28 2025-07-24 Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien Gmbh Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika
CN117670883B (zh) * 2024-01-31 2024-05-07 中国医学科学院北京协和医院 一种鉴别高低级别膀胱癌的方法、设备和系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2233269C2 (ru) * 1998-11-02 2004-07-27 Авентис Фарма Лимитед Замещенные анилиды, фармацевтическая композиция и способ лечения
JP3750494B2 (ja) 1999-08-31 2006-03-01 松下電器産業株式会社 半導体装置
WO2006093991A1 (en) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
EP3699162B1 (en) 2006-11-08 2022-06-29 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
ES2647538T3 (es) * 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
HUE034027T2 (en) 2008-08-01 2018-01-29 Univ Johns Hopkins Psma-binding agents and uses thereof
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
LT3481804T (lt) * 2016-06-10 2025-02-25 The Johns Hopkins University Radioaktyviai pažymėto prostatos specifinio membranos antigeno (psma) inhibitoriaus [18f]dcfpyl pagerinta sintezė

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048204A (ja) * 2008-08-01 2017-03-09 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａ結合剤及びその使用
JP2019055973A (ja) * 2008-08-01 2019-04-11 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａ結合剤及びその使用
JP2021095407A (ja) * 2008-08-01 2021-06-24 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａ結合剤及びその使用
JP7219497B2 (ja) 2008-08-01 2023-02-08 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａ結合剤及びその使用
JP7277113B2 (ja) 2008-08-01 2023-05-18 ザ ジョンズ ホプキンズ ユニヴァーシティー Ｐｓｍａ結合剤及びその使用

Also Published As

Publication number Publication date
US9861713B2 (en) 2018-01-09
HUE034027T2 (en) 2018-01-29
US10500292B2 (en) 2019-12-10
CY2023024I1 (el) 2024-02-16
CN102171187B (zh) 2017-07-28
LTPA2023534I1 (enExample) 2023-12-11
CY1125468T1 (el) 2025-05-09
CA2732632A1 (en) 2010-02-04
JP2016053025A (ja) 2016-04-14
DK3222615T3 (da) 2022-06-20
DK2318366T3 (en) 2017-08-21
HUE059436T2 (hu) 2022-11-28
PL2318366T3 (pl) 2017-10-31
AU2009276423B2 (en) 2014-10-30
CN107382846A (zh) 2017-11-24
US20180236110A1 (en) 2018-08-23
EP2318366A4 (en) 2011-12-14
HRP20171133T1 (hr) 2017-10-20
JP2021095407A (ja) 2021-06-24
FR23C1044I1 (fr) 2023-12-29
LTC2318366I2 (enExample) 2025-08-25
US20220088229A1 (en) 2022-03-24
EP3222615A1 (en) 2017-09-27
JP2015007058A (ja) 2015-01-15
SI3222615T1 (sl) 2022-11-30
KR101664855B1 (ko) 2016-10-11
EP2318366B1 (en) 2017-05-03
FIC20230033I1 (fi) 2023-11-02
PL3222615T3 (pl) 2022-09-26
US20110142760A1 (en) 2011-06-16
US8778305B2 (en) 2014-07-15
SMT201700371T1 (it) 2017-09-07
ES2634894T3 (es) 2017-09-29
US20200282083A1 (en) 2020-09-10
CY2023024I2 (el) 2024-12-13
JP6030724B2 (ja) 2016-11-24
HUS2300039I1 (hu) 2023-12-28
WO2010014933A3 (en) 2010-05-20
ES2914593T3 (es) 2022-06-14
KR20110038725A (ko) 2011-04-14
US20160114060A1 (en) 2016-04-28
SI2318366T1 (sl) 2017-10-30
US12070513B2 (en) 2024-08-27
RU2011107752A (ru) 2012-09-10
JP6524046B2 (ja) 2019-06-05
CN107382846B (zh) 2021-07-06
JP7277113B2 (ja) 2023-05-18
CY1119367T1 (el) 2018-02-14
US9226981B2 (en) 2016-01-05
PT3222615T (pt) 2022-06-20
NO2024006I1 (no) 2024-02-01
CA2987744A1 (en) 2010-02-04
AU2009276423A1 (en) 2010-02-04
NL301250I2 (nl) 2023-11-23
EP2318366A2 (en) 2011-05-11
CN102171187A (zh) 2011-08-31
JP2017048204A (ja) 2017-03-09
JP7219497B2 (ja) 2023-02-08
JP2019055973A (ja) 2019-04-11
WO2010014933A2 (en) 2010-02-04
EP3222615B1 (en) 2022-05-04
CN113563262A (zh) 2021-10-29
US20140369931A1 (en) 2014-12-18
PT2318366T (pt) 2017-08-02
JP2011529919A (ja) 2011-12-15
CA2732632C (en) 2018-01-09
HK1247197A1 (zh) 2018-09-21
US20250177578A1 (en) 2025-06-05
CA2987744C (en) 2022-11-15
JP5806765B2 (ja) 2015-11-10
LT3222615T (lt) 2022-08-25
EP4089074A1 (en) 2022-11-16
LT2318366T (lt) 2017-10-25
HRP20220742T1 (hr) 2022-10-28
FR23C1044I2 (fr) 2024-08-23
RU2494096C2 (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
JP7219497B2 (ja) Ｐｓｍａ結合剤及びその使用
HK40062845A (zh) Psma-結合劑及其用途
HK1161248A (en) Psma-binding agents and uses thereof
HK1161248B (en) Psma-binding agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140725

R150 Certificate of patent or registration of utility model

Ref document number: 5588441

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250